BioSpace News Archive

Synchron, a venture-backed brain data transfer company, announced that the U.S. Food and Drug Administration has approved its Investigational Device Exemption application for its flagship product, the StentrodeTM motor neuroprosthesis.

Bristol Myers SquibbBristol Myers SquibbBristol Myers Squibb reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance across the company.

Acceleron Pharma Inc., a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced net sales of REBLOZYL® as reported by its global collaborator, Bristol Myers Squibb, were approximately $128 million for the second quarter ended June 30, 2021.

XOMA Corporation (NASDAQ: XOMA), announced today NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation in pancreatic cancer by the U.S. Food and Drug Administration.

GenScript Biotech Corporation, a world-leading life sciences research and application service and product provider, announced that the U.S. Patent and Trademark Office has issued a notice of allowance for a patent application covering a novel Surrogate Virus Neutralization Test.

Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first patients in its Phase 1b trial of ZT-01.

TRACON Pharmaceuticals (NASDAQ:TCON), announced today that it will report its second quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, August 11, 2021.

SalioGen Therapeutics, a privately held biotechnology company developing durable and broadly applicable genetic medicines through Gene Coding, today announced that the Company has strengthened its management team with multiple leadership appointments of renowned experts in their respective fields.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 4, 2021 at 4:30 p.m. ET.

RELIEF THERAPEUTICS Holding AG announced that it has closed a definitive agreement to acquire all outstanding shares of AdVita Lifescience GmbH, a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases.